Piperazine azaspiro derivatives

US12398119B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Lei Zhang · Beijing, CN
• Erik Alphie LaChapelle · Uncasville, US
• Christopher Ryan Butler · Canton, US
• Natasha Mariam Kablaoui · Newton, US
• Michael Aaron Brodney · East Lyme, US
• Laura Ann McAllister · Pawcatuck, US
• Qingyi Yang · Lexington, US
• Christopher John Helal · Mystic, US
• Damien Webb · Brookline, US

Key dates

• Filing date: Oct 19, 2022
• Grant date: Aug 26, 2025
• Expiry date: Apr 17, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X1, X2, R1, R2, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.